Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
Yu-Kai TangZhe XuZhuo-Miao YeShi-Ran LiQin ZhouPublished in: Head & neck (2023)
In patients with R/M NPC, the regimen of tislelizumab plus GP, as the first-line treatment, is more cost-effective than the GP regimen in China.
Keyphrases